{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T13:27:20Z","timestamp":1771680440854,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy characterized by increased cellular adhesiveness. Vaso-occlusion (VOC) is the most prevalent disease complication of SCD that could be altered by genetic factors. L-Selectin and integrin alpha 2 (ITGA2) are 2 adhesion molecules linked to vasculopathy and inflammation. The current study aimed at detecting the prevalence of genetic variants of L-selectin and ITGA2 as possible molecular modulators and novel therapeutic targets in a cohort of pediatric SCD patients. Genotyping was performed by polymerase chain reaction restriction fragment length polymorphism technique for 100 SCD patients and 100 age and gender-matched unrelated healthy controls. The homomutant genotype of ITGA2 C807T was significantly higher in SCD patients compared with controls (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.001) and confirmed almost a 3-fold increased risk of moderate and severe attacks of VOC. There are significant adverse effects caused by the polymorphisms of ITGA2, and hence Egyptian SCD patients could benefit from the targeted therapies specifically against ITGA2 to ameliorate the severe course of the disease and improve the quality of life. However, further studies of genotypes and expression levels of these adhesion molecules during the attacks of VOC are recommended.<\/jats:p>","DOI":"10.1097\/mph.0000000000001839","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T15:40:53Z","timestamp":1589902853000},"page":"e707-e711","source":"Crossref","is-referenced-by-count":5,"title":["L-Selectin P213S and Integrin Alpha 2 C807T Genetic Polymorphisms in Pediatric Sickle Cell Disease Patients"],"prefix":"10.1097","volume":"42","author":[{"given":"Iman","family":"Shaheen","sequence":"first","affiliation":[{"name":"Clinical and Chemical Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervat","family":"Khorshied","sequence":"additional","affiliation":[{"name":"Clinical and Chemical Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha","family":"Abdel-Raouf","sequence":"additional","affiliation":[{"name":"Pediatric, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba","family":"Gouda","sequence":"additional","affiliation":[{"name":"Clinical and Chemical Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Kamal","sequence":"additional","affiliation":[{"name":"Pediatric, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly","family":"Abulata","sequence":"additional","affiliation":[{"name":"Clinical and Chemical Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reham","family":"Aboukhalil","sequence":"additional","affiliation":[{"name":"Clinical and Chemical Pathology"},{"name":"Department of Basic Medical Science, Unizha College of Medicine, Qassim University, Qassim, Kingdom of Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basant","family":"Meligy","sequence":"additional","affiliation":[{"name":"Pediatric, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00580-012-1469-7","article-title":"Prevalence of factor V Leiden (G1619A) and prothrombin gene (G20210A) mutation in Egyptian children with sickle cell disease","volume":"22","author":"Hamdy","year":"2013","journal-title":"Comp Clin Pathol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2350\/14-03-1452-OA.1","article-title":"Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1 and GSTP1) in Egyptian Pediatric Patients with Sickle Cell Disease","volume":"17","author":"Shiba","year":"2014","journal-title":"Pediatr Dev Pathol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.3324\/haematol.2014.108555","article-title":"Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellular aggregates in sickle cell anemia","volume":"99","author":"Dominical","year":"2014","journal-title":"Haematologica"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2147\/JBM.S191423","article-title":"Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date","volume":"10","author":"Riley","year":"2019","journal-title":"J Blood Med"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","article-title":"Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies","volume":"122","author":"Manwani","year":"2013","journal-title":"Blood"},{"key":"R6-20230918","first-page":"637","article-title":"Association of L-selectin gene polymorphism with clinical severity of sickle cell disease among Sudanese patients in Khartoum","volume":"4","author":"Elzubeir","year":"2016","journal-title":"Int J Multidisciplinary Curr Res"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5152\/balkanmedj.2013.7993","article-title":"Polymorphism in integrin ITGA2 is associated with ischemic stroke and altered serum cholesterol in Chinese individuals","volume":"31","author":"Lu","year":"2014","journal-title":"Balkan Med J"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.hoc.2005.08.002","article-title":"Sickle cell vaso-occlusion","volume":"19","author":"Chiang","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1751-553X.2007.00961.x","article-title":"l-selectin gene polymorphisms and complications of sickle cell disease","volume":"30","author":"Ugochukwu","year":"2008","journal-title":"Int J Lab Hematol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood-2015-09-618553","article-title":"Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease","volume":"127","author":"Telen","year":"2016","journal-title":"Blood"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/asheducation-2018.1.493","article-title":"New insights into the pathophysiology and development of novel therapies for sickle cell disease","volume":"2018","author":"Moerdler","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.mayocp.2018.08.001","article-title":"Advances in the treatment of sickle cell disease","volume":"93","author":"Kapoor","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","article-title":"Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease","volume":"127","author":"Hoban","year":"2016","journal-title":"Blood"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MOH.0000000000000136","article-title":"Update of hematopoietic cell transplantation for sickle cell disease","volume":"22","author":"Walters","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"e2020010","DOI":"10.4084\/mjhid.2020.010","article-title":"The evolving pharmacotherapeutic landscape for the treatment of sickle cell disease","volume":"12","author":"Ballas","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3324\/haematol.2018.207357","article-title":"Emerging disease-modifying therapies for sickle cell disease","volume":"104","author":"Carden","year":"2019","journal-title":"Haematologica"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcla.22264","article-title":"Protein Z and Endothelin-1genetic polymorphisms in pediatric Egyptian sickle cell disease","volume":"32","author":"Khorshied","year":"2018","journal-title":"J Clin Lab Anal"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.moh.0000190108.62414.06","article-title":"Leukocyte adhesion and the pathophysiology of sickle cell disease","volume":"3","author":"Okpala","year":"2006","journal-title":"Curr Opin Hematol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00218826","article-title":"DNA polymorphisms in adhesion molecule genes\u2014a new risk factor for early atherosclerosis","volume":"97","author":"Wenzel","year":"1996","journal-title":"Hum Genet"},{"key":"R21-20230918","first-page":"225","article-title":"L-selectin gene T668C mutation in type 1 diabetes patients and their first degree relatives","volume":"74","author":"Kretowski","year":"2000","journal-title":"Immunology"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/339077","article-title":"Association between single-nucleotide polymorphisms in selectin genes and immunoglobulin A nephropathy","volume":"70","author":"Takei","year":"2002","journal-title":"Am J Hum Genet"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1161\/01.STR.0000143788.87054.85","article-title":"Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation","volume":"35","author":"DeGraba","year":"2004","journal-title":"Stroke"},{"key":"R24-20230918","first-page":"99","article-title":"Possible implication Of LECAM-1 gene P213S polymorphism in the risk for advanced stages of diabetic nephropathy in patients with type 1 diabetes","volume":"XVI","author":"Panduru","year":"2009","journal-title":"Analele Universitatii din Oradea, Fascicula Biologie Tom"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.trsl.2014.02.001","article-title":"Plasma and serum L-selectin and clinical and subclinical the Multi-Ethnic Study of Atherosclerosis (MESA) cardiovascular disease","volume":"163","author":"Beradrdi","year":"2014","journal-title":"Transl Res"},{"key":"R26-20230918","first-page":"3560","article-title":"Integrin alpha2 [ITGA2] gene C807T allele polymorphism and clinical severity of sickle cell disease among Sudanese patients","volume":"5","author":"Elzubeir","year":"2017","journal-title":"Eur Acad Res"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1182\/blood-2003-10-3721","article-title":"Genetic variation responsible for mouse strain differences in integrin \u03b12 expression is associated with altered platelet responses to collagen","volume":"103","author":"Li","year":"2004","journal-title":"Blood"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00018-017-2490-4","article-title":"Integrin signaling in atherosclerosis","volume":"74","author":"Finney","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"e37882","DOI":"10.1371\/journal.pone.0037882","article-title":"Novel risk factors for premature peripheral arterial occlusive disease in non-diabetic patients: a case control study","volume":"8","author":"B\u00e9rard","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T06:14:07Z","timestamp":1695017647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001839","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,19]]}}}